Dermatophagoides Pteronyssinus

For Sublingual Immunotherapy (SLIT), the standard adult dose is typically one tablet (e.g., 12 SQ-HDM) administered once daily. Treatment is often initiated at any time of the year, as house dust mites are perennial allergens.

For Subcutaneous Immunotherapy (SCIT), the dosage is highly individualized and follows a two-phase approach:

1. 1Build-up Phase: Injections are given 1–3 times per week, starting with a very low concentration. The dose is gradually increased over 3 to 6 months.
2. 2Maintenance Phase: Once the effective therapeutic dose is reached, the frequency of injections is reduced to once every 2–4 weeks. This phase typically lasts for 3 to 5 years to ensure long-term desensitization.

The use of Dermatophagoides Pteronyssinus extracts in children depends on the specific product and formulation:

• SLIT Tablets: Some brands are FDA-approved for use in adolescents aged 12 through 17 years and adults up to 65 years. Safety and efficacy in children under 12 have not been fully established for all sublingual products.
• SCIT (Injections): Healthcare providers may use these extracts in children as young as 5 years old, depending on the severity of the allergy and the child's ability to tolerate the procedure and monitoring requirements.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the proteins are not cleared via the kidneys in a manner that would lead to systemic accumulation.

Hepatic Impairment

No dosage adjustments are necessary for hepatic impairment. The metabolism of allergenic proteins occurs via local cellular proteolytic pathways rather than the cytochrome P450 system.

Elderly Patients

Clinical trials for products like Odactra included patients up to age 65. Data for patients over 65 are limited. Healthcare providers should assess the cardiovascular status of elderly patients, as they may be less likely to tolerate the epinephrine required to treat a potential systemic reaction.

Sublingual Tablets

1. 1Remove the tablet from the foil packaging with dry hands.
2. 2Place the tablet immediately under the tongue.
3. 3Allow it to dissolve completely (usually takes about 10 seconds).
4. 4Do not swallow for at least one minute to allow for mucosal absorption.
5. 5Avoid eating or drinking for 5 minutes after the tablet has dissolved.
6. 6The first dose must be taken in a doctor's office under supervision for at least 30 minutes to monitor for serious allergic reactions.

Subcutaneous Injections

• These must be administered in a clinical setting by a trained professional.
• Patients must remain in the office for at least 30 minutes following each injection.

If a dose of the sublingual tablet is missed, skip the missed dose and resume the regular schedule the next day. Do not double the dose. If more than one dose is missed, contact your healthcare provider before restarting, as a dose adjustment may be necessary to prevent reactions. For missed injections, the schedule may need to be 'stepped back' to a lower dose depending on the length of the delay.

An overdose of allergenic extract increases the risk of severe local and systemic allergic reactions. Symptoms may include severe swelling of the tongue or throat, difficulty breathing, or hives. In the event of a suspected overdose or severe reaction, seek emergency medical attention immediately. If prescribed, an epinephrine autoinjector should be used as directed by your physician.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop treatment without medical guidance, as this can affect the efficacy and safety of the immunotherapy.

Side effects from Dermatophagoides Pteronyssinus extracts are most common during the first few weeks of treatment as the immune system begins to adapt. For sublingual administration, these include:

• Oral Pruritus (Itchy Mouth): A tingling or itching sensation on the tongue or roof of the mouth. This typically occurs within minutes of administration and lasts for 30–60 minutes.
• Throat Irritation: A 'scratchy' or sore feeling in the throat.
• Edema of the Mouth (Swelling): Mild swelling of the lips or sublingual area.
• Ear Pruritus: Itching deep within the ear canal, often due to shared nerve pathways with the throat.

• Nausea and Abdominal Pain: Some patients may experience mild stomach upset if they swallow the extract too quickly.
• Tongue Ulceration: Small, temporary sores under the tongue.
• Dysgeusia: A temporary change in taste perception.
• Urticaria (Hives): Localized or mild generalized skin itching.
• Oropharyngeal Swelling: More pronounced swelling of the back of the throat that does not interfere with breathing.

• Eosinophilic Esophagitis (EoE): Chronic inflammation of the esophagus characterized by difficulty swallowing (dysphagia) or chest pain.
• Laryngeal Edema: Significant swelling of the voice box area.
• Systemic Allergic Reactions: Reactions occurring far from the site of administration, such as generalized rashes or mild wheezing.

> Warning: Stop taking Dermatophagoides Pteronyssinus and call your doctor or emergency services immediately if you experience any of the following symptoms of Anaphylaxis:

• Difficulty Breathing: Wheezing, chest tightness, or shortness of breath.
• Throat Tightness: A feeling that the airway is closing or a sudden change in voice (hoarseness).
• Severe Swelling: Rapid swelling of the face, lips, tongue, or throat.
• Dizziness or Fainting: A sudden drop in blood pressure (hypotension) leading to lightheadedness or loss of consciousness.
• Rapid Pulse: A racing heart accompanied by a sense of doom.
• Severe Gastrointestinal Distress: Intense vomiting or cramping immediately following a dose.

When used correctly under medical supervision, Dermatophagoides Pteronyssinus extracts do not typically cause long-term organ toxicity. The primary long-term consideration is the development of Eosinophilic Esophagitis. Patients who develop persistent heartburn, difficulty swallowing, or food getting stuck in the throat should be evaluated by a specialist. Most patients find that the local side effects (mouth itching) diminish significantly after the first 1–3 months of daily use.

Sublingual products containing Dermatophagoides Pteronyssinus (such as Odactra) carry an FDA Black Box Warning regarding the risk of severe allergic reactions.

Summary of Warning:

• This medication can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.
• Do not initiate treatment in patients with severe, unstable, or uncontrolled asthma.
• Patients must be observed in a clinical setting for at least 30 minutes after the first dose.
• Patients must be prescribed an epinephrine autoinjector and trained on its use while taking this medication.
• Treatment may not be suitable for patients who are not candidates for epinephrine (e.g., those with certain heart conditions).

Report any unusual symptoms or side effects to your healthcare provider to ensure your treatment plan remains safe and effective.

Dermatophagoides Pteronyssinus immunotherapy is a potent biological treatment that requires careful patient selection. It is not a 'rescue' medication and will not provide immediate relief during an acute allergy attack or asthma flare-up. Patients must be committed to a long-term treatment plan, often lasting several years, to achieve clinical benefit.

As noted in the side effects section, the FDA has mandated a Black Box Warning for sublingual house dust mite extracts. The primary concern is Anaphylaxis. Because this treatment is administered at home (after the first dose), patients must be able to recognize the signs of a systemic reaction and be physically and mentally capable of administering an epinephrine injection if necessary.

• Asthma Status: Treatment should be withheld if a patient is experiencing an acute asthma exacerbation. Patients with severe, uncontrolled asthma are at a significantly higher risk for life-threatening reactions to immunotherapy.
• Oral Health: For sublingual tablets, treatment should be paused if the patient has open sores in the mouth, recent oral surgery (including tooth extraction), or significant gum inflammation. These conditions can increase the systemic absorption of the allergen, raising the risk of a reaction.
• Eosinophilic Esophagitis: Patients with a history of eosinophilic esophagitis should generally avoid this treatment, as it can exacerbate the condition.
• Epinephrine Suitability: Before starting, your doctor will ensure you can safely use epinephrine. Certain conditions, such as severe hypertension or unstable angina, may make the use of epinephrine (and thus immunotherapy) more risky.

• Initial Observation: A mandatory 30-minute observation period after the first dose to monitor for immediate hypersensitivity.
• Asthma Monitoring: Regular peak flow meter checks or spirometry may be recommended for patients with a history of asthma.
• Visual Inspection: Patients should periodically check their mouth and throat for persistent sores or significant swelling.

Dermatophagoides Pteronyssinus extracts generally do not cause drowsiness or cognitive impairment. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until cleared by a medical professional.

There is no direct chemical interaction between alcohol and Dermatophagoides Pteronyssinus. However, alcohol consumption can cause vasodilation and may theoretically increase the speed of allergen absorption in the mouth. It is also important to remain sober so that any potential allergic symptoms can be accurately identified and managed.

If treatment is stopped for more than a few days, do not resume without consulting your doctor. A 're-escalation' of the dose may be required. Unlike many medications, there is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the allergy symptoms will likely return if the course of immunotherapy was not completed (usually 3–5 years).

> Important: Discuss all your medical conditions, especially respiratory or heart issues, with your healthcare provider before starting Dermatophagoides Pteronyssinus.

While there are few absolute drug-drug contraindications, the following combinations are generally avoided due to safety concerns regarding the management of potential reactions:

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications can block the effects of epinephrine. If a patient on a beta-blocker has an anaphylactic reaction to the dust mite extract, the standard treatment (epinephrine) may be ineffective, potentially leading to a fatal outcome.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): Some studies suggest that ACE inhibitors may increase the risk of severe systemic reactions or interfere with the body's natural compensatory mechanisms during an allergic reaction.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the metabolism of epinephrine, leading to prolonged or exaggerated effects if an emergency injection is required.
• Other Allergen Immunotherapies: Taking multiple types of immunotherapy (e.g., dust mite tablets plus grass pollen shots) can have a cumulative effect on the immune system, potentially increasing the frequency of local or systemic side effects.

• Antihistamines: While often used to manage minor side effects, regular use of potent antihistamines can mask the 'early warning signs' of a systemic reaction, such as mild itching or hives, preventing the patient from taking action before the reaction becomes severe.
• Topical Steroids (Oral): Use of steroid creams or rinses in the mouth may alter the mucosal immune response and affect the efficacy of sublingual tablets.

• Spicy or Acidic Foods: Consuming these immediately after a sublingual dose may increase oral irritation or discomfort.
• Food Allergies: If a patient has a severe food allergy, they should avoid taking their dust mite extract immediately after an accidental exposure to that food, as the immune system is already in a 'primed' or hyper-reactive state.

There are no well-documented interactions between Dermatophagoides Pteronyssinus and common herbal supplements like St. John's Wort or Ginkgo Biloba. However, supplements that have potent anti-inflammatory effects (like high-dose Curcumin or Boswellia) should be disclosed to your doctor, as they may theoretically influence the immune modulation process.

• Skin Prick Tests: Treatment with the extract will eventually decrease the reactivity of the skin to dust mite allergens. This is an intended effect but should be noted if the patient undergoes diagnostic testing for other allergies.
• Specific IgE/IgG4 Testing: Immunotherapy will cause a rise in allergen-specific IgG4 and an initial rise followed by a long-term decrease in specific IgE. These changes are expected markers of the treatment's effect on the immune system.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those for blood pressure or heart conditions.

Dermatophagoides Pteronyssinus extracts must NEVER be used in the following circumstances:

• Severe or Uncontrolled Asthma: Patients with a Forced Expiratory Volume (FEV1) below 80% of predicted, or those with recent exacerbations, are at high risk for fatal bronchospasm during a reaction.
• History of Severe Systemic Allergic Reaction: Anyone who has had a prior life-threatening reaction to house dust mite immunotherapy.
• Eosinophilic Esophagitis (EoE): Because immunotherapy can cause or worsen EoE, a known history of this condition is an absolute contraindication for sublingual forms.
• Hypersensitivity to Inactive Ingredients: This includes sensitivity to gelatin, mannitol, or magnesium stearate used in tablet formulations.

Conditions requiring a careful risk-benefit analysis by a specialist:

• Severe Cardiovascular Disease: Patients who may not tolerate the stress of a systemic reaction or the side effects of epinephrine.
• Autoimmune Disorders: While not strictly forbidden, the use of immunotherapy in patients with active systemic autoimmune diseases (like Lupus or Rheumatoid Arthritis) is controversial and requires close monitoring.
• Malignancy: Patients with active cancer are typically not started on immunotherapy, as the immune system is already compromised or highly stressed.
• Beta-Blocker Therapy: As previously mentioned, this is a significant safety concern due to epinephrine resistance.

Patients allergic to Dermatophagoides pteronyssinus often show cross-reactivity with Dermatophagoides farinae (the American house dust mite) because they share similar protein structures. Many immunotherapy products contain a 50/50 mix of both species to provide broad protection. There is also a known cross-sensitivity between house dust mites and certain crustaceans (like shrimp or lobster) due to a shared protein called tropomyosin. Patients with severe shellfish allergies should inform their doctor, although they can usually still safely receive dust mite immunotherapy.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Dermatophagoides Pteronyssinus.

• Pregnancy Category: Typically classified as Category B or C depending on the specific manufacturer.
• Risk Summary: There are no adequate and well-controlled studies in pregnant women. However, clinical practice guidelines generally suggest that immunotherapy should not be initiated during pregnancy because of the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen to the baby).
• Maintenance: If a woman is already on a stable maintenance dose and becomes pregnant, the treatment can often be continued if it is well-tolerated, as the risk of a reaction is lower during the maintenance phase than during the build-up phase.

It is not known whether Dermatophagoides Pteronyssinus allergenic proteins are excreted in human milk. However, since these are large proteins that are processed locally in the oral mucosa or injection site, systemic absorption is minimal. Most experts consider it safe to continue immunotherapy while breastfeeding, as the proteins would likely be digested in the infant's stomach even if small amounts were present in the milk.

• Approved Age: Sublingual tablets (like Odactra) are generally approved for ages 12 through 65.
• Efficacy: Studies have shown significant reduction in symptom scores and rescue medication use in adolescents.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development in children.
• Considerations: Children must be mature enough to follow instructions (e.g., not swallowing the tablet for one minute) and to report symptoms of an allergic reaction.

Clinical trials included a limited number of patients aged 65 and older. The primary concern in the elderly is the presence of comorbid conditions (like heart disease) that would make an allergic reaction more dangerous. Pharmacokinetic changes associated with age (reduced kidney or liver function) do not significantly affect the use of this biological product.

No dosage adjustment is required. The clearance of the active allergenic proteins does not depend on renal function. However, patients with severe renal disease should be monitored for their overall ability to handle systemic stress.

No dosage adjustment is required. The liver's cytochrome P450 system is not involved in the processing of these allergenic proteins.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or have underlying organ dysfunction.

Dermatophagoides Pteronyssinus extract acts as an immunobiological modifier. The extract contains major allergens, specifically Der p 1 (a cysteine protease) and Der p 2 (a lipid-binding protein). When these proteins are presented to the immune system in a controlled, repetitive manner, they interact with dendritic cells and T-lymphocytes. This leads to the induction of Peripheral Tolerance. The key molecular event is the shift from a pro-allergic Th2 cytokine profile (IL-4, IL-5, IL-13) to a regulatory profile (IL-10, TGF-β), which suppresses IgE production and promotes the synthesis of protective IgG4 antibodies.

The pharmacodynamic effect is measured by a decrease in the 'Early Phase Response' (immediate histamine release) and the 'Late Phase Response' (tissue eosinophilia and inflammation). Clinical onset is slow; it typically takes 8 to 14 weeks of daily treatment to observe a noticeable reduction in allergy symptoms. The duration of effect can be long-lasting, with studies suggesting that a completed 3-year course can provide benefit for several years after treatment is discontinued.

| Parameter | Value |

|---|---|

| Bioavailability | Low (systemically); High (mucosal capture) |

| Protein Binding | N/A (processed by immune cells) |

| Half-life | N/A (biological degradation) |

| Tmax | Local capture within minutes |

| Metabolism | Proteolytic degradation in lysosomes |

| Excretion | Not renally excreted as intact protein |

• Molecular Formula: Complex mixture of proteins (e.g., Der p 1: C1155H1801N315O352S13) |
• Molecular Weight: Varies by protein (Der p 1 is ~25 kDa; Der p 2 is ~14 kDa) |
• Solubility: Soluble in aqueous buffers and physiological saline |
• Structure: Globular proteins with specific epitopes (binding sites) for IgE and T-cell receptors.

Dermatophagoides Pteronyssinus is classified as a Standardized Allergenic Extract. It belongs to the broader category of Antigen-Specific Immunotherapy. Related medications include extracts for Dermatophagoides farinae, Timothy grass pollen (Phleum pratense), and Ragweed pollen (Ambrosia artemisiifolia).